- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | ImageneBio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | ImageneBio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.04. | ImageneBio $30 Million Private Placement Ignites Stock | 1 | Benzinga.com | ||
| 13.04. | ImageneBio stock jumps on $30M financing | 1 | Seeking Alpha | ||
| 13.04. | ImageneBio: 30 Millionen US-Dollar für Medikament gegen Haarausfall und Dermatitis | 1 | Investing.com Deutsch | ||
| 13.04. | ImageneBio, Inc.: ImageneBio Announces $30 Million Private Placement | 1 | GlobeNewswire (USA) | ||
| 13.04. | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 17.03. | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 10.03. | ImageneBio, Inc. GAAP EPS of -$9.64 | 1 | Seeking Alpha | ||
| 10.03. | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.03. | ImageneBio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 10.03. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.02. | ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer | 1 | Investing.com | ||
| 10.02. | ImageneBio, Inc.: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer | 1.057 | GlobeNewswire (Europe) | Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion... ► Artikel lesen | |
| 12.11.25 | ImageneBio, Inc.: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team | 540 | GlobeNewswire (Europe) | $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to... ► Artikel lesen | |
| 01.08.25 | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 259 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen | |
| 25.07.25 | Ikena Oncology, Inc.: Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million | 410 | GlobeNewswire (Europe) | The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will... ► Artikel lesen | |
| 23.07.25 | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company | 340 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema... ► Artikel lesen | |
| 15.07.25 | Ikena Oncology, Inc.: Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals | 384 | GlobeNewswire (Europe) | Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc.... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,810 | +2,30 % | Blockbuster, Gold und Insiderverkäufe - Bayer AG, Evotec, North Arrow Minerals | Der erneute israelische Angriff im Libanon blockiert die eh schon unsicheren US-Iran-Gespräche massiv. Da Teheran die Hisbollah im Libanon unterstützt und den Frieden mit den USA an einen Frieden zwischen... ► Artikel lesen | |
| BIOGEN | 177,86 | +1,14 % | Biogen Inc.: Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. | Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 developmentCAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,978 | +0,41 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,150 | -0,75 % | Abnehm-Medikamente: Milliardenmarkt Adipositas: Der nächste Herausforderer für Novo und Lilly? | © Foto: JoNel Aleccia - picture alliance / ASSOCIATED PRESSViking Therapeutics startet die klinische Prüfung eines neuen Adipositas-Wirkstoffs. Damit wächst die Konkurrenz im Milliardenmarkt für Adipositas-Therapien.Viking... ► Artikel lesen | |
| INFLARX | 1,692 | -0,47 % | InflaRx NV im Höhenflug: Was hinter dem Kursanstieg wirklich steckt - Was das für Ihr Depot bedeutet | ||
| INTELLIA THERAPEUTICS | 13,660 | -0,15 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 81,35 | -5,35 % | Guggenheim kürt ABIVAX zum Top-Pick im Biotech-Sektor | ||
| HALOZYME THERAPEUTICS | 62,58 | -0,16 % | Halozyme Therapeutics, Inc.: Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 | SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero... ► Artikel lesen | |
| IBIO | 1,525 | +6,49 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| IMMUNITYBIO | 6,860 | -0,15 % | Jim Cramer Says "Let ImmunityBio Be Your Speculation" to a Caller | ||
| IMMATICS | 8,905 | +0,85 % | Immatics N.V. - 6-K, Report of foreign issuer | ||
| LAKEFRONT BIOTHERAPEUTICS | 25,500 | 0,00 % | Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer | ||
| CELLECTAR BIOSCIENCES | 2,490 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| MANNKIND | 3,459 | +2,13 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen |
Das Unternehmen IMAGENEBIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.